Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?

In patients with metastatic ER+, HER2-, ESR1-mutated breast cancer, how would duration of prior ET+CDK4/6i response impact your use of elacestrant?

• Reserve elacestrant for patients with a prolonged response (≥12 months) to prior ET+CDK4/6i
• Use elacestrant for all patients with ESR1 mutations, regardless of the duration of response to prior ET+CDK4/6i
• I am not using elacestrant and prefer other standard-of-care options
• Other